Investor pressure pushes drugmaker mergers, trades

By LINDA A. JOHNSON, Associated Press Published: April 23, 2014
Advertisement
;

Drugmakers eager to satisfy shareholders by boosting profits and share prices are wheeling, dealing and in one case even making trades like a pro sports team looking to shake up its roster. The moves could spur more mergers and acquisitions in the industry.

Swiss drugmaker Novartis AG on Tuesday said it’s trading its vaccine business for GlaxoSmithKline Plc’s cancer drug business and selling its veterinary drug business to Eli Lilly and Co. Meanwhile, Canadian drugmaker Valeant Pharmaceuticals International Inc. said it teamed up with activist investor Bill Ackman in a bid for Botox maker Allergan that could be worth about $45 billion.

Amid easier financing and low interest rates, four smaller drugmakers also have announced bids of $3 billion or more to acquire competitors since January, according to data and research firm The Mergermarket Group. The biggest is a $23 billion bid by Forest Laboratories Inc. for Actavis Inc.

The deals partly reflect a push by the pharmaceutical industry to boost sales and cut costs as drugmakers look for ways to return to the growth investors have come to expect after the bullish last two decades, when they continually churned out new blockbusters: drugs with annual sales of more than a billion dollars.

Most drugmakers have since seen revenue flatline or even dip under a tidal wave of cheaper generic competition. Others see the wave coming — Novartis, for instance, is awaiting generic competition to its blockbuster blood-pressure drug Diovan — and are trying to lessen the impact.

Continue reading this story on the...